The affordable growth investing strategy attempts to find a middle ground between paying up for rapid expansion and hunting for deep value bargains. It targets companies that show strong revenue and earnings momentum, but still trade at reasonable multiples relative to their future potential, while also maintaining acceptable financial health and profitability. The idea is to avoid companies that are growing fast but are priced for perfection, as well as those that are cheap for a reason.
A Closer Look at the Numbers
Liquidia Corp (NASDAQ:LQDA) operates in the biopharmaceutical space, focusing on rare cardiopulmonary diseases. Based on the latest available fundamental data, the stock earns a composite fundamental rating of 6 out of 10. While that overall score is solid, the standout driver is the company's exceptional growth profile.
Growth: The Core of the Thesis
The growth rating of 8 out of 10 is the primary reason this stock fits the affordable growth screen. The numbers are dramatic, largely reflecting a transition from a development-stage to a commercial-stage business.
- Revenue explosion: Revenue surged by a staggering 1,936.66% over the last year.
- Consistent expansion: The average revenue growth over the past several years sits at 192.46% per year.
- Earnings follow: Earnings per share (EPS) grew by 110.13% in the last year, turning positive.
Looking forward, this trajectory is expected to continue, albeit at a slower pace. Analysts project average annual EPS growth of 63.09% and revenue growth of 61.75% over the next few years. This combination of past and future growth makes the company a clear candidate for a growth-focused strategy.
Valuation: Paying a Reasonable Price
This is where the "affordable" part of the thesis is tested. The trailing Price/Earnings (P/E) ratio of 499.63 looks extremely expensive on the surface and relative to the broader S&P 500. However, the valuation picture becomes much more interesting when looking forward.
- Forward P/E: The Price/Forward Earnings ratio is 13.64, which is actually cheaper than 81.25% of its industry peers and well below the S&P 500's forward average of 21.32.
- PEG Ratio: The Price/Earnings to Growth (PEG) ratio is considered low, suggesting that the current price is reasonable when adjusted for the expected growth rate.
- Industry context: Compared to the rest of the Pharmaceuticals industry, LQDA is cheaper on metrics like Enterprise Value to EBITDA and Price to Free Cash Flow, indicating it is not the most expensive name in its sector.
The high trailing P/E is a result of past years of losses, but the forward estimates point to a company that is now profitable and growing into its valuation. For an affordable growth screen, the forward metrics are what matter.
Health and Profitability: The Supporting Pillars
A growth company can quickly become a poor investment if it is drowning in debt or burning cash without a path to profitability. LQDA scores a 6 out of 10 in both Health and Profitability, which is considered decent enough to pass the screen's filter.
Key health highlights include:
- No outstanding debt, giving the company a clean balance sheet.
- A strong Altman-Z score of 14.20, indicating a very low risk of bankruptcy.
- A current ratio of 2.22, showing it can comfortably meet short-term obligations.
On the profitability side, the company demonstrates that its recent growth is not just a top-line story:
- Return on Equity (ROE) is 20.54%, outperforming 90.10% of industry peers.
- Return on Invested Capital (ROIC) is a strong 14.29%.
- Operating Margin of 15.81% is among the best in its peer group.
These metrics confirm that the company is generating real returns from its operations, which supports the valuation and gives confidence that the growth is sustainable.
Why This Stock Fits the Screen
Liquidia Corp is a textbook example of what an affordable growth screen is designed to catch. The growth rating is excellent, and while the trailing valuation looks extreme, the forward valuation is compelling when paired with that growth trajectory. The financial health is sound, and profitability is now in positive territory.
To review the full breakdown of these ratings and the underlying financial data, you can read the detailed fundamental analysis report for Liquidia Corp.
For investors who want to find similar opportunities where strong growth meets reasonable valuation and solid financials, this screen is a useful starting point. You can run the exact Affordable Growth screen used to select LQDA and explore more results here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
Liquidia Corp (NASDAQ:LQDA): An Affordable Growth Stock With Explosive Revenue Momentum and Reasonable Forward Valuation
The affordable growth investing strategy attempts to find a middle ground between paying up for rapid expansion and hunting for deep value bargains. It targets companies that show strong revenue and earnings momentum, but still trade at reasonable multiples relative to their future potential, while also maintaining acceptable financial health and profitability. The idea is to avoid companies that are growing fast but are priced for perfection, as well as those that are cheap for a reason.
A Closer Look at the Numbers
Liquidia Corp (NASDAQ:LQDA) operates in the biopharmaceutical space, focusing on rare cardiopulmonary diseases. Based on the latest available fundamental data, the stock earns a composite fundamental rating of 6 out of 10. While that overall score is solid, the standout driver is the company's exceptional growth profile.
Growth: The Core of the Thesis
The growth rating of 8 out of 10 is the primary reason this stock fits the affordable growth screen. The numbers are dramatic, largely reflecting a transition from a development-stage to a commercial-stage business.
Looking forward, this trajectory is expected to continue, albeit at a slower pace. Analysts project average annual EPS growth of 63.09% and revenue growth of 61.75% over the next few years. This combination of past and future growth makes the company a clear candidate for a growth-focused strategy.
Valuation: Paying a Reasonable Price
This is where the "affordable" part of the thesis is tested. The trailing Price/Earnings (P/E) ratio of 499.63 looks extremely expensive on the surface and relative to the broader S&P 500. However, the valuation picture becomes much more interesting when looking forward.
The high trailing P/E is a result of past years of losses, but the forward estimates point to a company that is now profitable and growing into its valuation. For an affordable growth screen, the forward metrics are what matter.
Health and Profitability: The Supporting Pillars
A growth company can quickly become a poor investment if it is drowning in debt or burning cash without a path to profitability. LQDA scores a 6 out of 10 in both Health and Profitability, which is considered decent enough to pass the screen's filter.
Key health highlights include:
On the profitability side, the company demonstrates that its recent growth is not just a top-line story:
These metrics confirm that the company is generating real returns from its operations, which supports the valuation and gives confidence that the growth is sustainable.
Why This Stock Fits the Screen
Liquidia Corp is a textbook example of what an affordable growth screen is designed to catch. The growth rating is excellent, and while the trailing valuation looks extreme, the forward valuation is compelling when paired with that growth trajectory. The financial health is sound, and profitability is now in positive territory.
To review the full breakdown of these ratings and the underlying financial data, you can read the detailed fundamental analysis report for Liquidia Corp.
For investors who want to find similar opportunities where strong growth meets reasonable valuation and solid financials, this screen is a useful starting point. You can run the exact Affordable Growth screen used to select LQDA and explore more results here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making any investment decisions.
Read full article here »